TW202108171A - 穩定的低黏度抗體調配物及其用途 - Google Patents

穩定的低黏度抗體調配物及其用途 Download PDF

Info

Publication number
TW202108171A
TW202108171A TW109113601A TW109113601A TW202108171A TW 202108171 A TW202108171 A TW 202108171A TW 109113601 A TW109113601 A TW 109113601A TW 109113601 A TW109113601 A TW 109113601A TW 202108171 A TW202108171 A TW 202108171A
Authority
TW
Taiwan
Prior art keywords
formulation
hours
antibody
days
months
Prior art date
Application number
TW109113601A
Other languages
English (en)
Chinese (zh)
Inventor
歐圖 薩盧加
曼裘里 岡谷立
凱文 雷伯特
雅廷 高卡恩
Original Assignee
法商賽諾菲公司
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70295163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202108171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 法商賽諾菲公司, 美商健臻公司 filed Critical 法商賽諾菲公司
Publication of TW202108171A publication Critical patent/TW202108171A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW109113601A 2019-04-23 2020-04-23 穩定的低黏度抗體調配物及其用途 TW202108171A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
EP20305145 2020-02-17
EP20305145.3 2020-02-17

Publications (1)

Publication Number Publication Date
TW202108171A true TW202108171A (zh) 2021-03-01

Family

ID=70295163

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109113601A TW202108171A (zh) 2019-04-23 2020-04-23 穩定的低黏度抗體調配物及其用途

Country Status (15)

Country Link
US (1) US20220218607A1 (https=)
EP (1) EP3958896A1 (https=)
JP (2) JP7671697B2 (https=)
KR (1) KR20220004104A (https=)
CN (1) CN114286690A (https=)
AU (1) AU2020262231A1 (https=)
BR (1) BR112021021099A2 (https=)
CA (1) CA3137464A1 (https=)
CO (1) CO2021015561A2 (https=)
IL (1) IL287435A (https=)
MA (1) MA55750A (https=)
MX (1) MX2021012968A (https=)
SG (1) SG11202111740PA (https=)
TW (1) TW202108171A (https=)
WO (1) WO2020216847A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022006882A (es) * 2019-12-05 2022-11-08 Sanofi Aventis Us Llc Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
BR112012021576A2 (pt) * 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
MA55750A (fr) 2022-03-02
AU2020262231A1 (en) 2021-12-16
KR20220004104A (ko) 2022-01-11
IL287435A (en) 2021-12-01
CA3137464A1 (en) 2020-10-29
EP3958896A1 (en) 2022-03-02
JP2022530050A (ja) 2022-06-27
WO2020216847A1 (en) 2020-10-29
CN114286690A (zh) 2022-04-05
SG11202111740PA (en) 2021-11-29
BR112021021099A2 (pt) 2021-12-14
MX2021012968A (es) 2022-01-18
JP7671697B2 (ja) 2025-05-02
JP2025087851A (ja) 2025-06-10
US20220218607A1 (en) 2022-07-14
CO2021015561A2 (es) 2021-12-10

Similar Documents

Publication Publication Date Title
TW202108171A (zh) 穩定的低黏度抗體調配物及其用途
JP2024542073A (ja) 抗体薬物結合体のための特異的共役
JP5661553B2 (ja) 改良された抗体分子を含有する製剤
RU2653447C2 (ru) Стабилизированные содержащие антитела жидкие композиции
JP6734774B2 (ja) ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用
ES2349779T3 (es) Formulaciones de anticuerpos y de proteínas a concentración elevada.
AU2012244764B2 (en) Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
ES2788515T3 (es) Formulaciones liofilizadas y acuosas de anticuerpos anti-CD40
WO2020090979A1 (ja) 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
TWI682788B (zh) 包含ｇｍ－ｃｓｆ中和化合物之液態調配物
KR20190008320A (ko) 약학 조성물
CN106163567A (zh) 抗体‑药物缀合物冻干制剂
CN109563161A (zh) 用于提高抗体稳定性的缓冲制剂
ES2806946T3 (es) Composición farmacéutica estable de la proteína de fusión TNFR:Fc etanercept
US20170348427A1 (en) Pharmaceutical formulations and methods of use thereof
AU2011351414A1 (en) Pharmaceutical formulation comprising a biopharmaceutical drug
TW202034961A (zh) 含有標識部－抗人類抗體Ｆａｂ片段複合體之醫藥組成物
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
CA3193104A1 (en) Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
US20230414760A1 (en) Pharmaceutical formulation
CN119095584A (zh) 抗gm-csf抗体的液体药物配制品及其用途
US20220280615A1 (en) Immune tolerant elastin-like recombinant peptides and methods of use
BR112022021690B1 (pt) Anticorpos multiespecíficos, biespecíficos ou monoclonais, composição farmacêutica, usos dos mesmos, método de produção dos anticorpos multiespecíficos, biespecíficos ou monoclonais, kit, e moléculas biespecíficas semelhantes a anticorpo de três cadeias
BR122022022755B1 (pt) Anticorpos monoclonais biespecíficos, seus usos e seu método de produção, composição farmacêutica e kit
CN116510006A (zh) 抗trbv9抗体的药物组合物及其用途